-
Internal medicine journal · Oct 2022
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
- Xavier Brennan, Barbara Withers, Andrew Jabbour, Sam Milliken, Eugene Kotlyar, Keith Fay, David Ma, Kavitha Muthiah, Nada Hamad, Anthony Dodds, Nikki Bart, Anne Keogh, Chris Hayward, Peter Macdonald, and John Moore.
- Cardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
- Intern Med J. 2022 Oct 1; 52 (10): 182618301826-1830.
AbstractCardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.© 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..